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Background: The aim of this study was to apply a new method for selecting a 
few genes, out of thousands, as plausible markers of a disease. 
Methods: Hierarchical clustering technique was used along with Support Vector 
Machine (SVM) and Naïve Bayes (NB) classifiers to select marker-genes of three 
types of breast cancer. In this method, at each step, one subject is left out and the 
algorithm iteratively selects some clusters of genes from the remainder of subjects 
and selects a representative gene from each cluster. Then, classifiers are constructed 
based on these genes and the accuracy of each classifier to predict the class of left-
out subject is recorded. The classifier with higher precision is considered superior. 
Results: Combining classification techniques with clustering method resulted in 
fewer genes with high degree of statistical precision. Although all classifiers 
selected a few genes from pre-determined highly ranked genes, the precision did 
not decrease. SVM precision was 100% with 22 genes instead of 50 genes while 
the NB resulted in higher precision of 97.95% in this case. When 20 highly ranked 
genes selected to be fed to the algorithm, same precision was obtained using 6 and 
5 genes with SVM and NB classifiers respectively. 
Conclusion: Using hybrid method could be effective in choosing fewer number 
of plausible marker genes so that the classification precision of these markers is 
increased. In addition, this method enables detecting new plausible markers that 
their association to disease under study is not biologically proved. 
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Introduction 
 
Cancer ranks first health threatening is-
sue and breast cancer is the leading malig-
nancy among Iranian women
1,2. According to 
American Cancer Society report, estimated 
number of deaths due to breast cancer in 2012 
ranks second after lung cancer among US 
women while estimated new cases of breast 
cancer in 2012 is above the rest kinds of can-
cer
3. Trend of cancer was increasing from 
1994 to 1999. This trend was decreasing from 
1999 to 2006 with 2% per year attributed to 
the reduction in the use of Menopausal 
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Hormone Therapy (MHT)
4. According to 
reports published in 2005 to 2007, 12.15% of 
females born today, would experience breast 
cancer in their life; i.e. one out of 8
3. 
Early detection of breast cancer could 
result in mortality reduction and improve pa-
tients’ prognosis. Although, mammography 
and other screening methods could acceptably 
detect breast cancer in early stages, but they 
would be partially effective and even ineffec-
tive in specific age groups
5. Cancer is consi-
dered a heterogeneous disease in terms of 
many aspects including its cellularity, different 
genetic alternation, and diverse clinical beha-
vior that could be, in turn, due to heterogene-
ity of malignant cells and the patients’ baseline 
factors. Now, cancer is classified based on 
clinical and histomorphological features that 
they could only partially reflect this hetero-
geneity and this will lead to lower possibility 
of perfect diagnosis, prognosis and prescrip-
tion of relevant treatments. Beyond the diag-
nosis, determining the type of cancer is crucial 
to adopt relevant therapies. Because anti-can-
cer agents do not differentiate between nor-
mal and cancerous cells and sometimes lead to 
disastrous toxicity and an inconsistent efficacy. 
On the other hand, development of innova-
tive drugs that selectively target cancer cells is 
of great interest and this adds to the impor-
tance of diagnosis and differentiating molecu-
lar events related to incidence and develop-
ment of cancer
6. Since this phenomenon is 
under influence of several genes, biological 
techniques that enable studying hundreds or 
thousands of molecular factors simultaneously 
are of high interest. These techniques could 
untangle the complexities existing between 
diseases and cell physiology. 
US Food and Drug Administration 
(FDA) encourages using new technologies 
such as microarrays that could improve the 
assessment of medical products to promote 
the public health. Using this state-of-the-art 
technology in various clinical and diagnostic 
disciplines would have an important impact 
on public health, epidemiology, and other 
fields. Hamelin et al. studied virulence genes 
in environmental E. coli isolates using microar-
rays that were impossible before
7. Ramaswamy 
et al. conducted a microarray analysis to 
identify primary and metastatic adenocarci-
noma
8. By the advent of such a technology, it 
would be possible to diagnose diseases in ear-
lier stages and accurately define the type of a 
multi-class disease and use the best treatment 
as well as comparing the efficacy of various 
available treatments. This, certainly, could pro-
mote public health and prevent the growing 
burden, of all kind, of diseases on a society by 
screening and timely and accurately detection 
of these health threats. 
DNA Microarray first was developed 
and used by Schenaet al. in the early 1990
9. It 
is an analytical tool that makes quick and pre-
cise genomic assessment possible. In this 
technology, gene expression levels in healthy 
and diseased tissues are evaluated and differ-
ences are determined. Hereby, genes with dif-
ferent levels of expression are identified and 
considered as potential markers of the disease 
to be studied in future studies. 
In 1998, Eisenet al. clustered genes to 
analyze the gene expression patterns and 
identify genes with similar expression level
10. 
Golub et al. used DNA microarray to diag-
nose and predict the class of cancerous tissues 
with Acute Myeloid Leukemia (AML) and 
Acute Lymphoblastic Leukemia (ALL)
11. 
DNA microarray is a silicon chip on 
which thousands of single stranded oligonuc-
leotides so called targets are spotted.  These 
sequences are attached to the chip in two 
ways: Delivery or Contact Print in which tar-
gets are products of molecular techniques that 
are transferred on the chip. The second pro-
cedure is Synthesis or Photolithography. In 
this method, targets are constructed on the 
chip directly. Every chip is partitioned to dis-
tinct rows and columns called cells. Thou-
sands of oligonucleotides of a gene are synthe-
sized in a cell using a robot; each cell pertain-
ing to a gene. This way, each cell contains only 
one type of oligonucleotides.  Jafari Koshki et al.: A Comparison of Selective Classification … 
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Then, mRNA from both healthy and 
diseased tissues is extracted. Two types of flo-
rescent tags is attached to the end of these two 
types of single stranded mRNAs such that 
they turn into red or green under laser radia-
tion. These mRNA samples are washed and 
combined in equal amounts and poured on 
the chip. Therefore, single stranded mRNAs 
would bind to complementary single stranded 
oligonucleotides spotted on the chip. After a 
while, the chip is washed and put under the 
laser radiation and red or green lights are pro-
duced by tags. In each cell, there exist some 
red and some green tags. Thus, spectrum of 
colors would appear on the chip depending on 
the relative amount of these tags. Finally, pro-
duced spectrum is scanned and turned into 
digits using computers. These digits pertaining 
to relative density of tags indicate the relative 
expression level of genes in healthy and dis-
eased tissues
6,9. 
Breast cancer is one of major diseases 
with regard its prevalence, incidence, and cost-
burden issues
3. As a health problem, it could 
be screened in various ways such as mammo-
graphy
3,12. However, evaluating novel 
screening procedures to update or replace 
previous methods by more ones that are relia-
ble is appealing. Hence, we used this disease as 
a case study due to its importance and availa-
bility of relevant data to clarify microarray ap-
plication in health related areas. However, mi-
croarray analysis application scope is much 
wider and could be applied to various health 
problems in a same manner. 
Statistical and machine learning me-
thods are widely used in DNA microarray data 
analyses. The aim of this study was to com-
bine these techniques to select fewer genes as 
markers of a disease via an algorithm. Breast 
cancer data was used to assess the perfor-
mance of the algorithm according to its preci-
sion in predicting the type of cancer of a new 
patient. 
 
 
Materials and Methods 
 
This cross-sectional study was done 
based on data prepared by Farmer et al. by 
expression level of 22,215 genes from 49 pa-
tients with previously known type of cancer: 
basal, luminal, and apocrine
13. Biopsies were 
taken from patients enrolled in a clinical trial 
before any treatment. The patients’ characte-
ristics and the trial duration were not men-
tioned. We used all data on gene expression 
levels obtained from these patients. This data 
is freely available on NCBI-GEO database 
with accession number GSE1561. The data 
were normalized before usage. 
 
Statistical Modeling 
Clustering is a famous statistical tech-
nique to discover similar groups in a dataset
14. 
We used hierarchical clustering method to 
cluster the most similar genes in a group. 
Among different distance criteria, we 
used average linkage distance: 
d(p, q)=1-r(Gp, Gq) 
wherer (Gp, Gq) represents Pearson cor-
relation coefficient between genes p and q. 
Distance between two clusters each containing 
a number of genes is calculated as average of 
distance between pairwise genes. 
Bayes learning is a useful machine 
learning technique often called Naïve Bayes. A 
Bayesian technique is as follows. Consider x 
representing feature (genes here) and y is the 
target function with range V. A set of learning 
samples is prepared and the machine is ex-
pected to classify new sample x=(G1, G2, … 
,Gn)  and predict its label. Bayes classifier as-
signs the label with maximum possibility to 
this sample
15. This maximum probability is 
called νMAP and calculated as: 
 
Cortes et al. introduced a class of 
hyperplanes with sign function to allocate a 
new sample to one of spaces created by op-
timal plane
16. Consider observations {xi, yi}, 
i=1, 2, … ,L that xi indicates variable values of Health Promotion Perspectives, Vol. 3, No. 1, 2013; P: 129-134 
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ith subject and yi the class of ith subject. Ob-
servations are classified into two groups with a 
hyperplane. Among all possible separating 
hyperplanes, we find the plane 
w.x+b=0 such that has maximum distance 
from both groups. Therefore, the decision 
function to classify a new observation would 
be based on sign function below: 
 
where b is calculated by: 
 
 
The Algorithm to select markers 
We followed following steps to find 
best markers based on their precision in de-
termining the class of new samples: 
First, relief-F filtering technique, intro-
duced by Kira and Rendel
17, was performed 
on the data. This would sort genes upon their 
relevance to represent the data. Then an arbi-
trary number of genes with highest ranks are 
selected. Now, the average linkage hierarchical 
clustering is done and dendrogram is plotted. 
A line is put on the upper part of dendrogram 
and is moved downward for clusters to be 
created. At first, we have only one cluster 
containing all selected genes. Moving the line 
would divide this cluster to more and more 
sub-clusters. At each step, one gene is ex-
tracted from each sub-cluster. This gene, 
which is the representative gene of pertaining 
cluster, would be the gene with minimum 
summed squared distance from other genes in 
that sub-cluster. When these representative 
genes are selected, one sample is excluded 
from subjects and the classifier is constructed 
according to these genes. Then, the class of 
the left-out gene is specified by the classifier. 
Now, the left-out subject is returned to the 
sample, another subject is excluded from 
sample, and the process is repeated until all 
subjects are excluded and returned to sample 
one by one. When this process is completed 
for this step, the rate of accurately classified 
subjects is considered as the classifier’s per-
formance
18. Aforementioned process is re-
peated at each step of the line movement and 
the prediction precision is recorded for the 
respective number of clusters or genes. 
At the final step, the number of sub-
clusters or genes equals the number of genes 
selected at the earliest stage. 
This algorithm was implemented in 
Waikato Environment for Knowledge Analy-
sis (WEKA)
19,20 and MATLAB 7.0. 
 
Results 
 
Table 1 shows the prediction precision 
for 50 selected genes with highest ranks. 
  
Table 1: Number and precision of candidate markers based on 50 highly ranked genes as the input of the algorithm 
 
NCBI accession number 
for selected markers 
(Number, Preci-
sion(%)) for candidate 
markers 
Precision (%) 
for all selected 
genes 
Classification 
method 
209604_s_at, 214431_at, 205009_at, 209459_s_at, 
205186_at, 214053_at, 204580_at, 204822_at, 
204667_at, 207039_at, 203574_at, 203780_at, 
205376_at, 203453_at, 203636_at, 209900_s_at, 
208484_at, 203256_at, 214079_at, 205030_at, 
217528_at, 214451_at 
22, 100  100  SVM 
209603_at, 205186_at, 205819_at, 204667_at, 
205376_at, 203636_at, 209900_s_at, 208484_at, 
203256_at, 214079_at, 205030_at, 217528_at 
12, 97.95  95.91  NB 
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Table 2: Number and precision of candidate markers based on 20 highly ranked genes as the input of the algorithm 
 
NCBI accession number 
for selected markers 
(Number, Preci-
sion(%)) for candidate 
markers 
Precision (%) 
for all selected 
genes 
Classification 
method 
209603_at, 204667_at, 204580_at, 218963_s_at, 
214079_at, 205030_at  6, 97.95  97.95  SVM 
209604_s_at, 204580_at, 218963_s_at, 214079_at, 
205030_at  5, 95.91  95.91  NB 
 
The result indicates that for SVM clas-
sifier, one could construct a function that clas-
sifies a new patient with higher accuracy using 
22 genes instead of 50 genes. The result for 
NB classifier is even more interesting. Using 
all selected 50 genes, the precision is 95.91% 
but 100% for 22 selected genes by the algo-
rithm. The algorithm was implemented for 20 
highly ranked genes separately. The results are 
shown in Table 2. This table suggests that we 
could gain same precision with smaller num-
ber of genes. 
 
Discussion 
 
Traditional techniques usually fall short 
of perfect diagnosis, prediction, adopting the 
best treatment and evaluating the prescribed 
treatments as well. Therefore, researchers en-
deavor to make improvements in each area. In 
this regard, DNA microarray analysis has been 
center of attention in recent years and many 
studies have been done to improve this tech-
nology. Using this technology helps the re-
searchers to circumvent previous limitations 
of the traditional laboratory tools. Hamelin et 
al. used microarrays to study the virulence 
genes in environmental E. coli isolates that had 
technological limitations before
7. Ramaswamy 
et al. distinguished primary and metastatic 
adenocarcinoma by using a microarray 
analysis
8. They reported a challenging result 
contradicting the previous notion that 
metastases arise from rare cells within a 
primarytumor that have the ability to 
metastasize. Microarrays could be utilized to 
detect a disease accurately and quickly and 
help to decrease the cost of diseases and 
improve the quality of life in the society. By 
developments in this area, microarray would 
be able to serve as a cheap and quick 
screening tool before too long. 
Wang et al. assessed the performance of 
this algorithm on three datasets
18. They found 
that hybrid method could result in fewer 
marker-genes. Chittenden et al. used this me-
thod to classify coronary artery disease
21. They 
evaluated transcriptional correlation in mono-
cyte types from these patients and fewer genes 
with higher degree of significance. Same result 
was found on independent datasets. They also 
reported that selected marker-genes had roles 
in molecular functions and biological processes. 
The results from present study show that many 
of genes selected by the algorithm have a role 
or are related to breast cancer: GATA3, AR, 
NBR1, ESR1, ERBB4 and GHR to name a 
few
12. ER expression level was known as the 
source of differentiation between luminaland 
basal types. Farmer et al. reported that ERBB4 
was commoner in molecular apocrine than the 
other groups
13. These facts support the appro-
priateness of the hybrid algorithm in cancer 
type differentiations. Nevertheless, functional-
ity of some of genes identified as markers of 
cancer differentiation is not clear yet. This 
could illuminate a path for future studies to 
clarify their possible relation to breast cancer. 
DNA microarray analysis enables us to 
study thousands of genes simultaneously, 
which leads us to patterns and markers that 
their roles are not known in diseases as well. In 
the bioinformatics context, statistical tech-
niques are considered as the final chain of data 
mining process. In this manuscript, we tried to 
briefly introduce microarray technology and 
evaluate the performance of a hybrid approach Health Promotion Perspectives, Vol. 3, No. 1, 2013; P: 129-134 
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combining two statistical techniques. The bur-
den of health problems, that could be pre-
vented by effective diagnostic and screening in 
advance, imposes a great demand on new tech-
niques to improve existing diagnostic and 
screening methods
3. Microarray is a new ap-
proach that is widely used in treatment assess-
ment, disease diagnosis and classification. We, 
here, used this technique to highlight its ad-
vantage in cancer classification. It could be ap-
plied to another health related issues from dif-
ferent viewpoints by designing a relevant study 
and gathering data on the subject.  
 
Conclusion  
 
We used some of well-known statistical 
techniques via an algorithm. However, other 
classification and clustering methods or other 
statistical and machine learning techniques 
could be used in this algorithm and results 
compared with methods used in this study. 
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